Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577
Debt
Debt-to-Equity Ratio0.06
Current Ratio12.06
Quick Ratio12.06
Price-To-Earnings
Trailing P/E Ratio-2.79
Forward P/E Ratio-7.56
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.01 per share
Price / Book3.34
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees34
Outstanding Shares20,700,000
Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions
What is Allena Pharmaceuticals' stock symbol?
Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."
How were Allena Pharmaceuticals' earnings last quarter?
Allena Pharmaceuticals (NASDAQ:ALNA) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.05. View Allena Pharmaceuticals' Earnings History.
What price target have analysts set for ALNA?
6 Wall Street analysts have issued twelve-month price targets for Allena Pharmaceuticals' shares. Their forecasts range from $21.00 to $61.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $32.90 in the next year. View Analyst Ratings for Allena Pharmaceuticals.
What are Wall Street analysts saying about Allena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Allena Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (5/11/2018)
- 2. Wedbush analysts commented, "We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset." (12/18/2017)
Who are some of Allena Pharmaceuticals' key competitors?
Some companies that are related to Allena Pharmaceuticals include BAVARIAN NORDIC/S (BVNRY), Coherus Biosciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Novavax (NVAX), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), CASI Pharmaceuticals (CASI), Surface Oncology (SURF), Nightstar Therapeutics (NITE), Vericel (VCEL) and NanoString Technologies (NSTG).
Who are Allena Pharmaceuticals' key executives?
Allena Pharmaceuticals' management team includes the folowing people:
- Dr. Alexey L. Margolin Ph.D., Co-Founder, CEO & Director (Age 65)
- Dr. Louis Brenner, Pres & COO (Age 48)
- Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 58)
- Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 53)
- Mr. Hugh Wight, VP of Technical Operations
When did Allena Pharmaceuticals IPO?
(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When did Allena Pharmaceuticals' lock-up period expire?
Allena Pharmaceuticals' lock-up period expired on Tuesday, May 1st. Allena Pharmaceuticals had issued 5,333,333 shares in its initial public offering on November 2nd. The total size of the offering was $74,666,662 based on an initial share price of $14.00. Since the expiration of Allena Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has Allena Pharmaceuticals been receiving favorable news coverage?
News coverage about ALNA stock has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allena Pharmaceuticals earned a news sentiment score of 0.25 on Accern's scale. They also assigned media stories about the company an impact score of 45.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Allena Pharmaceuticals' major shareholders?
Allena Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (1.98%), BlackRock Inc. (1.12%), JPMorgan Chase & Co. (0.95%), Millennium Management LLC (0.44%), Citadel Advisors LLC (0.05%) and Wells Fargo & Company MN (0.05%). Company insiders that own Allena Pharmaceuticals stock include Bessemer Venture Partners Vii and James N Topper. View Institutional Ownership Trends for Allena Pharmaceuticals.
Which institutional investors are selling Allena Pharmaceuticals stock?
Which institutional investors are buying Allena Pharmaceuticals stock?
ALNA stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Millennium Management LLC, Citadel Advisors LLC, Wells Fargo & Company MN and BlackRock Inc.. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals.
How do I buy shares of Allena Pharmaceuticals?
Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allena Pharmaceuticals' stock price today?
One share of ALNA stock can currently be purchased for approximately $13.38.
How big of a company is Allena Pharmaceuticals?
Allena Pharmaceuticals has a market capitalization of $269.04 million. The company earns $-21,650,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.
How can I contact Allena Pharmaceuticals?
Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.
MarketBeat Community Rating for Allena Pharmaceuticals (ALNA)
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
